表紙:生物学的製剤フィル/フィニッシュサービス市場:第2版
市場調査レポート
商品コード
1024362

生物学的製剤フィル/フィニッシュサービス市場:第2版

Biologics Fill / Finish Services Market (2nd Edition) by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins,

出版日: | 発行: Roots Analysis | ページ情報: 英文 539 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.26円
生物学的製剤フィル/フィニッシュサービス市場:第2版
出版日: 2021年05月31日
発行: Roots Analysis
ページ情報: 英文 539 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧米市場における生物学的製剤フィル/フィニッシュサービスに対する将来的な需要に対応するため、これらの地域に拠点を置く受託サービスプロバイダーは、製剤の製造やフィル/フィニッシュ用の追加の生産能力を獲得するために多額の投資を行っています。

現在、約170社が生物学的製剤のフィル/フィニッシュサービスを積極的に提供していると言われています。サービスプロバイダーの一般的な傾向として、この分野の関係者は、フィル/フィニッシュサービスに対する需要の高まりに対応するために、最新の技術革新を積極的に取り入れようとしており、オペレーションコストの削減や効率の向上、進化する安全性や規制要件への対応を行い、競合企業との差別化を図っています。

当レポートでは、世界の生物学的製剤フィル/フィニッシュサービス市場について調査分析し、現在の市場規模と将来の機会について、体系的な情報を提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 生物学的製剤フィル/フィニッシュサービスプロバイダー:競合情勢

  • 章の概要
  • 生物学的製剤フィル/フィニッシュサービスプロバイダー:全体の市場情勢

第5章 企業の競争力分析

  • 章の概要
  • 調査手法と主要パラメーター
  • 北米の生物学的製剤フィル/フィニッシュサービスプロバイダー
  • 欧州の生物学的製剤フィル/フィニッシュサービスプロバイダー
  • アジア太平洋地域・その他の地域の生物学的製剤フィル/フィニッシュサービスプロバイダー

第6章 北米の生物学的製剤フィル/フィニッシュサービスプロバイダー

  • 章の概要
  • AbbVie Contract Manufacturing
  • BioPharma Solutions
  • BioReliance
  • Catalent Biologics
  • Patheon

第7章 欧州の生物学的製剤フィル/フィニッシュサービスプロバイダー

  • 章の概要
  • Boehringer Ingelheim BioXcellence
  • Lonza
  • Pierre Fabre
  • Recipharm
  • Wacker Biotech

第8章 アジア太平洋地域の生物学的製剤フィル/フィニッシュサービスプロバイダー

  • 章の概要
  • Asymchem
  • Samsung Biologics
  • Syngene
  • Takara Bio
  • WuXi Biologics

第9章 パートナーシップとコラボレーション

  • 章の概要
  • パートナーシップモデル
  • 生物学的製剤フィル/フィニッシュサービスプロバイダー:パートナーシップとコラボレーションのリスト

第10章 最近の拡張

  • 章の概要
  • 生物学的製剤フィル/フィニッシュサービスプロバイダー:最近の拡張
  • 関与する生物学的製剤

第11章 生産能力分析

第12章 需要分析

第13章 生物学的製剤の製造・フィル/フィニッシュの主要業績評価指標

第14章 地域別の能力評価

第15章 市場規模と機会分析

  • 章の概要
  • 予測手法
  • 全体の生物学的製剤フィル/フィニッシュサービス市場
  • アンプルの生物学的製剤フィル/フィニッシュサービス市場
  • カートリッジの生物学的製剤フィル/フィニッシュサービス市場
  • シリンジの生物学的製剤フィル/フィニッシュサービス市場
  • バイアルの生物学的製剤フィル/フィニッシュサービス市場

第16章 将来の成長機会

  • 章の概要
  • バイオ医薬品のパイプラインの増加
  • フィル/フィニッシュ作業のアウトソーシングの増加
  • 薬剤の自己投与への関心の高まり
  • 無菌フィル/フィニッシュ技術の進歩
  • アジア太平洋地域の成長機会

第17章 ケーススタディ:フィル/フィニッシュ作業におけるロボットシステム

第18章 ケーススタディ:無菌フィル/フィニッシュ用のRTU包装コンポーネント

第19章 結論

第20章 インタビュー記録

第21章 付録1:表形式データ

第22章 付録2:企業・組織のリスト

図表

List Of Tables

  • Table 3.1 Best-Selling Drugs of 2019
  • Table 4.1 Biologics Fill / Finish Service Providers: List of Companies
  • Table 4.2 Biologics Fill / Finish Service Providers: Information on Type of Packaging
  • Table 4.3 Biologics Fill / Finish Service Providers: Information on Type of Biologic Involved
  • Table 4.4 Biologics Fill / Finish Service Providers: Information on Scale of Operation
  • Table 4.5 Biologics Fill / Finish Service Providers: Information on Additional Services Offered
  • Table 4.6 Biologics Fill / Finish Service Providers: Information on Fill / Finish Capacity
  • Table 6.1 Biologics Fill / Finish Service Providers in North America: List of Profiled Companies
  • Table 6.2 AbbVie Contract Manufacturing: Company Overview
  • Table 6.3 AbbVie Contract Manufacturing: Overview of Service Portfolio
  • Table 6.4 AbbVie Contract Manufacturing: Sterile Manufacturing Facilities
  • Table 6.5 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
  • Table 6.6 BioPharma Solutions: Company Overview
  • Table 6.7 BioPharma Solutions: Overview of Service Portfolio
  • Table 6.8 BioPharma Solutions: Sterile Manufacturing Facilities
  • Table 6.9 BioPharma Solutions: Recent Developments and Future Outlook
  • Table 6.10 BioReliance: Company Overview
  • Table 6.11 BioReliance: Overview of Service Portfolio
  • Table 6.12 BioReliance: Sterile Manufacturing Facilities
  • Table 6.13 BioReliance: Recent Developments and Future Outlook
  • Table 6.14 Catalent Biologics: Company Overview
  • Table 6.15 Catalent Biologics: Overview of Service Portfolio
  • Table 6.16 Catalent Biologics: Sterile Manufacturing Facilities
  • Table 6.17 Catalent Biologics: Recent Developments and Future Outlook
  • Table 6.18 Patheon: Company Overview
  • Table 6.19 Patheon: Overview of Service Portfolio
  • Table 6.20 Patheon: Sterile Manufacturing Facilities
  • Table 6.21 Patheon: Recent Developments and Future Outlook
  • Table 7.1 Biologics Fill / Finish Service Providers in Europe: List of Profiled Companies
  • Table 7.2 Boehringer Ingelheim BioXcellence: Company Overview
  • Table 7.3 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
  • Table 7.4 Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
  • Table 7.5 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
  • Table 7.6 Lonza: Company Overview
  • Table 7.7 Lonza: Overview of Service Portfolio
  • Table 7.8 Lonza: Sterile Manufacturing Facilities
  • Table 7.9 Lonza: Recent Developments and Future Outlook
  • Table 7.10 Pierre Fabre: Company Overview
  • Table 7.11 Pierre Fabre: Overview of Service Portfolio
  • Table 7.12 Pierre Fabre: Sterile Manufacturing Facilities
  • Table 7.13 Pierre Fabre: Recent Developments and Future Outlook
  • Table 7.14 Recipharm: Company Overview
  • Table 7.15 Recipharm: Overview of Service Portfolio
  • Table 7.16 Recipharm: Sterile Manufacturing Facilities
  • Table 7.17 Recipharm: Recent Developments and Future Outlook
  • Table 7.18 Wacker Biotech: Company Overview
  • Table 7.19 Wacker Biotech: Overview of Service Portfolio
  • Table 7.20 Wacker Biotech: Sterile Manufacturing Facilities
  • Table 7.21 Wacker Biotech: Recent Developments and Future Outlook
  • Table 8.1 Biologics Fill / Finish Service Providers in Asia-Pacific: List of Profiled Companies
  • Table 8.2 Asymchem: Company Overview
  • Table 8.3 Asymchem: Overview of Service Portfolio
  • Table 8.4 Asymchem: Sterile Manufacturing Facilities
  • Table 8.5 Asymchem: Recent Developments and Future Outlook
  • Table 8.6 Syngene: Company Overview
  • Table 8.7 Syngene: Overview of Service Portfolio
  • Table 8.8 Syngene: Recent Developments and Future Outlook
  • Table 8.9 Takara Bio: Company Overview
  • Table 8.10 Takara Bio: Overview of Service Portfolio
  • Table 8.11 Takara Bio: Recent Developments and Future Outlook
  • Table 8.12 WuXi Biologics: Company Overview
  • Table 8.13 WuXi Biologics: Overview of Drug Product Services
  • Table 8.14 WuXi Biologics: Sterile Manufacturing Facilities
  • Table 8.15 WuXi Biologics: Recent Developments and Future Outlook
  • Table 9.1 Biologics Fill / Finish Service Providers: Partnerships and Collaborations, 2013-2020
  • Table 9.2 Partnerships and Collaborations: Information on Types of Services Offered, 2013-2020
  • Table 9.3 Partnerships and Collaborations: Information on Types of Biologics Involved, 2013-2020
  • Table 10.1 Biologics Fill / Finish Service Providers: Recent Expansions, 2013-2021 (till January)
  • Table 10.2 Recent Expansions, 2013-2021 (till January): Information on Type of Packaging
  • Table 10.3 Recent Expansions, 2013-2021 (till January): Information on Types of Services
  • Table 10.4 Recent Expansions, 2013-2021 (till January): Information on Types of Biologics
  • Table 11.1 Average Fill / Finish Capacity for Ampoules (Number of Units Filled) by Company Size (Sample Data Set)
  • Table 11.2 Average Fill / Finish Capacity for Cartridges (Number of Units Filled) by Company Size (Sample Data Set)
  • Table 11.3 Average Fill / Finish Capacity for Syringes (Number of Units Filled) by Company Size (Sample Data Set)
  • Table 11.4 Average Fill / Finish Capacity for Vials (Number of Units Filled) by Company Size (Sample Data Set)
  • Table 11.5 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size
  • Table 11.6 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size
  • Table 11.7 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size
  • Table 11.8 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size
  • Table 11.9 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Company Size
  • Table 11.10 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size
  • Table 11.11 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size
  • Table 11.12 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size
  • Table 12.1 Global Biologics Fill / Finish Services: Annual Supply for Outsourcing, 2021-2030 (Million Liters)
  • Table 16.1 Patent Expiry of Biologics, 2021-2023
  • Table 17.1 Biologics Fill / Finish Service Providers: Information on Fill / Finish Equipment Used
  • Table 17.2 List of Pharmaceutical Robotics Manufacturers
  • Table 17.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Container
  • Table 18.1 List of Companies Supplying Ready-to-Use Packaging Components
  • Table 19.1 Biologics Fill / Finish Service Providers: Summary of the Report
  • Table 21.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
  • Table 21.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
  • Table 21.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
  • Table 21.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
  • Table 21.5 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging
  • Table 21.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Involved and Type of Packaging Form
  • Table 21.7 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
  • Table 21.8 Biologics Fill / Finish Service Providers: Distribution by Type of Additional Services Offered
  • Table 21.9 AbbVie: Annual Revenues, 2015 - 2020 (USD Billion)
  • Table 21.10 Merck KGaA: Annual Revenues, 2014 - 9M 2020 (EUR Billion)
  • Table 21.11 Merck KGaA: Annual Revenues by Business Segment, 9M 2020 (EUR Billion)
  • Table 21.12 Catalent Biologics: Annual Revenues, 2015 - 2020 (USD Billion)
  • Table 21.13 Thermo Fisher Scientific: Annual Revenues, 2014 - 9M 2020 (USD Billion)
  • Table 21.14 Patheon: Annual Revenues, 2012 - H1 2017 (USD Million)
  • Table 21.15 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
  • Table 21.16 Boehringer Ingelheim BioXcellence: Annual Revenues, 2014 - H1 2020 (EUR Billion)
  • Table 21.17 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Million)
  • Table 21.18 Pierre Fabre: Annual Revenues, 2015 - 2018 (EUR Billion)
  • Table 21.19 Recipharm: Annual Revenues, 2012 - 9M 2020 (SEK Billion)
  • Table 21.20 Recipharm: Revenues by Business Divisions, 9M 2020 (SEK Billion)
  • Table 21.21 Wacker Chemie: Annual Revenues, 2015 - 2020 (EUR Billion)
  • Table 21.22 Asymchem: Annual Revenues, 2015 - 2019 (USD Million)
  • Table 21.23 Samsung Biologics: Annual Revenues, FY 2016 - FY 2020 (KRW Billion)
  • Table 21.24 Syngene: Annual Revenues, FY 2016 - 9M FY 2021 (INR Million)
  • Table 21.25 Takara Bio: Annual Revenues, FY 2016 - H1 FY 2021 (JPY Billion)
  • Table 21.26 WuXi Biologics: Annual Revenues, 2014 - H1 2020 (RMB Million)
  • Table 21.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2020
  • Table 21.28 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 21.29 Partnerships and Collaborations: Distribution by Scale of Operation
  • Table 21.30 Partnerships and Collaborations: Distribution by Types of Services Offered
  • Table 21.31 Partnerships and Collaborations: Distribution by Types of Processes
  • Table 21.32 Partnerships and Collaborations: Distribution by Types of Biologics Involved and Type of Services Offered
  • Table 21.33 Partnerships and Collaborations: Most Active Players
  • Table 21.34 Partnerships and Collaborations: Geographical Analysis
  • Table 21.35 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 21.36 Partnerships and Collaborations: Distribution by Geographical Location of Facilities
  • Table 21.37 Recent Expansions: Distribution by Year of Expansion, 2013-2021 (till January)
  • Table 21.38 Recent Expansions: Distribution by Type of Expansion
  • Table 21.39 Recent Expansions: Distribution by Type of Packaging
  • Table 21.40 Recent Expansions: Distribution by Type of Expansion and Type of Service
  • Table 21.41 Recent Expansions: Distribution by Type of Biologic Involved
  • Table 21.42 Recent Expansions: Distribution by Type of Biologic and Scale of Operation
  • Table 21.43 Recent Expansions: Distribution by Geographical Location
  • Table 21.44 Recent Expansions: Distribution by Most Active Players
  • Table 21.45 Recent Expansions: Distribution by Location of Expansion Project
  • Table 21.46 Recent Expansions in North America: Distribution by Type of Service Offered and Type of Biologic Involved
  • Table 21.47 Recent Expansions in Europe: Distribution by Type of Service and Type of Biologic
  • Table 21.48 Recent Expansions in Asia-Pacific: Distribution by Type of Service and Type of Biologic
  • Table 21.49 Capacity for Filling Ampoules: Distribution by Company Size (Sample Data Set)
  • Table 21.50 Capacity for Filling Cartridges: Distribution by Company Size (Sample Data Set)
  • Table 21.51 Capacity for Filling Syringes: Distribution by Company Size (Sample Data Set)
  • Table 21.52 Capacity for Filling Vials: Distribution by Company Size (Sample Data Set)
  • Table 21.53 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Type of Packaging (Million Units)
  • Table 21.54 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Company Size (Million Units)
  • Table 21.55 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Scale of Operation (Million Units)
  • Table 21.56 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Headquarters (Million Units)
  • Table 21.57 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Table 21.58 Global Fill / Finish Capacity (by Fill Volume): Distribution by Type of Packaging (Kilo Liters)
  • Table 21.59 Global Fill / Finish Capacity (by Fill Volume): Distribution by Company Size (Kilo Liters)
  • Table 21.60 Global Fill / Finish Capacity (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
  • Table 21.61 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
  • Table 21.62 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Kilo Liters)
  • Table 21.63 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size (Thousand Units)
  • Table 21.64 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
  • Table 21.65 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
  • Table 21.66 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Table 21.67 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size (Liters)
  • Table 21.68 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Scale of Operation (Liters)
  • Table 21.69 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Headquarters (Liters)
  • Table 21.70 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
  • Table 21.71 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size (Thousand Units)
  • Table 21.72 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
  • Table 21.73 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
  • Table 21.74 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Table 21.75 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size (Liters)
  • Table 21.76 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Scale of Operation (Liters)
  • Table 21.77 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Headquarters (Liters)
  • Table 21.78 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
  • Table 21.79 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Company Size
  • Table 21.80 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
  • Table 21.81 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
  • Table 21.82 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Table 21.83 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size (Liters)
  • Table 21.84 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Scale of Operation (Liters)
  • Table 21.85 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Headquarters (Liters)
  • Table 21.86 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
  • Table 21.87 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size (Thousand Units)
  • Table 21.88 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
  • Table 21.89 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
  • Table 21.90 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Table 21.91 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size (Liters)
  • Table 21.92 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Scale of Operation (Liters)
  • Table 21.93 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Headquarters (Liters)
  • Table 21.94 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
  • Table 21.95 Global Demand for Biologics Fill / Finish Services (Million Liters)
  • Table 21.96 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Packaging (Kilo Liters)
  • Table 21.97 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Biologic (Kilo Liters)
  • Table 21.98 Global Demand for Biologics Fill / Finish Services: Distribution by Therapeutic Area (Kilo Liters)
  • Table 21.99 Global Demand for Biologics Fill / Finish Services: Distribution by Geographical Location (Kilo Liters)
  • Table 21.100 Global Biologics Fill / Finish Services: Demand and Supply, 2021-2030
  • Table 21.101 Overall Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 21.102 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
  • Table 21.103 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.104 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.105 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.106 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
  • Table 21.107 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
  • Table 21.108 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
  • Table 21.109 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.110 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.111 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.112 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
  • Table 21.113 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
  • Table 21.114 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.115 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.116 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.117 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
  • Table 21.118 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
  • Table 21.119 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.120 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.121 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.122 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
  • Table 21.123 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.124 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.125 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.126 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
  • Table 21.127 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.128 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.129 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.130 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.131 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.132 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.133 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.134 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.135 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.136 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
  • Table 21.137 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.138 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.139 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.140 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
  • Table 21.141 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.142 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.143 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.144 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.145 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.146 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.147 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.148 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.149 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.150 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
  • Table 21.151 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.152 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.153 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.154 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
  • Table 21.155 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.156 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.157 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.158 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.159 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.160 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.161 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.162 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.163 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.164 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
  • Table 21.165 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.166 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.167 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.168 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
  • Table 21.169 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.170 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.171 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.172 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.173 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.174 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.175 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 21.176 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Table 21.177 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 21.178 New Molecular Entities Approved by the FDA, 2011-2020

List Of Companies

  • 1. 3P Biopharmaceuticals
  • 2. Aalto Scientific
  • 3. ABB
  • 4. AbbVie
  • 5. AbbVie Contract Manufacturing
  • 6. Abzena
  • 7. ACG
  • 8. ACIC Pharmaceutical Machinery
  • 9. AdaptVac
  • 10. ADC Biotechnology
  • 11. Adimmune
  • 12. Advanced BioScience Laboratories
  • 13. Affinity Life Sciences
  • 14. Afton Scientific
  • 15. Agilis Biotherapeutics
  • 16. AJ Biologics
  • 17. Ajinomoto Bio-Pharma Services
  • 18. Akron Biotech
  • 19. AKSO
  • 20. Akums Drugs and Pharmaceuticals
  • 21. Alanza
  • 22. Alcami
  • 23. Alcon
  • 24. Aldevron
  • 25. Alkermes
  • 26. Althea
  • 27. Althea Technologies
  • 28. Amatsigroup
  • 29. Ambica Pharma Machines
  • 30. Amgen
  • 31. Amicus Therapeutics
  • 32. AMRI
  • 33. Anchiano Therapeutics
  • 34. Anchor Mark
  • 35. Anthos Therapeutics
  • 36. apceth Biopharma
  • 37. APG Europe
  • 38. Aptar Pharma
  • 39. Aptuit
  • 40. Arabio
  • 41. ARaymond Life
  • 42. Arch Biopartners
  • 43. ARISTO
  • 44. Aseptic Technologies
  • 45. Asklepios BioPharmaceutical
  • 46. AST
  • 47. AstraZeneca
  • 48. Asymchem
  • 49. Ausia BioTech
  • 50. Austrianova
  • 51. Automated Systems of Tacoma
  • 52. Avrio Biopharmaceuticals
  • 53. AWS Bio-Pharma Technologies
  • 54. Axcellerate Pharma
  • 55. Baccinex
  • 56. Bausch & Ströbel
  • 57. BAUSCH Advanced Technology Group (BATG)
  • 58. Bayer
  • 59. Berkshire Sterile Manufacturing
  • 60. Binex
  • 61. Bio Elpida
  • 62. Bio-Concept Laboratories
  • 63. BioConnection
  • 64. Biofabri
  • 65. Biogen
  • 66. BioMARC
  • 67. Biomay
  • 68. Biomedical Advanced Research and Development Authority (BARDA)
  • 69. BioNTech IMFS
  • 70. BioPharma Solutions
  • 71. BioReliance
  • 72. BioTechLogic
  • 73. BioTechnique
  • 74. BioTechniques
  • 75. Biovian
  • 76. BirgiMefar
  • 77. Boehringer Ingelheim BioXcellence
  • 78. Bolt Biotherapeutics
  • 79. Boston Children's Hospital
  • 80. Bristol-Myers Squibb
  • 81. Bryllan
  • 82. BSP Pharmaceuticals
  • 83. Burrard Pharmaceuticals
  • 84. Cangene Corporation
  • 85. Canton Biologics
  • 86. CARBOGEN AMCIS
  • 87. Catalent Biologics
  • 88. Celgene
  • 89. Cell Culture Company
  • 90. Cellin Technologies
  • 91. Celonic
  • 92. Cenexi
  • 93. Cerbios-Pharma
  • 94. Cerium Pharmaceuticals
  • 95. ChemPartner
  • 96. Chime Biologics
  • 97. China Gateway Biologics
  • 98. CinnaGen
  • 99. Citryll
  • 100. CMAB Biopharma
  • 101. CMC Biologics
  • 102. Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI)
  • 103. Cobra Biologics
  • 104. Cognate BioServices
  • 105. Coldstream Laboratories
  • 106. Colorado State University
  • 107. Columbus Venture Partners
  • 108. Comecer
  • 109. Cook Pharmica
  • 110. CordenPharma
  • 111. Creative Biolabs
  • 112. Crystal Pharma
  • 113. CureVac
  • 114. CytoDyn
  • 115. Cytovance Biologics
  • 116. Daikyo Seiko
  • 117. Dalton Pharma Services
  • 118. Dara Pharma
  • 119. Datwyler Sealing Solutions
  • 120. DENSO
  • 121. Dhruv Life Sciences
  • 122. Disposable Lab
  • 123. DM Bio
  • 124. DSM Pharmaceutical Products
  • 125. DWK Life Sciences
  • 126. EirGen Pharma
  • 127. EirGenix
  • 128. Eli Lilly
  • 129. EMA Pharmaceuticals
  • 130. Emcure Pharmaceuticals
  • 131. Emergent BioSolutions
  • 132. Esco Aster
  • 133. Etinpro
  • 134. EuBiologics
  • 135. EUCODIS Bioscience
  • 136. Eurofins BioPharma Product Testing Netherlands
  • 137. Eurofins Scientific
  • 138. EVER Pharma
  • 139. Exelead
  • 140. Experic
  • 141. Extract Technology
  • 142. FANUC America
  • 143. Fareva
  • 144. FinVector
  • 145. Formosa Laboratories
  • 146. Fresenius Kabi Contract Manufacturing
  • 147. FUJIFILM Diosynth Biotechnologies
  • 148. GC Pharma
  • 149. GEA
  • 150. Genentech
  • 151. GeneQuantum Healthcare
  • 152. Generic Specialities
  • 153. GenIbet Biopharmaceuticals
  • 154. Genovior Biotech
  • 155. Genprex
  • 156. Gerresheimer
  • 157. Getinge
  • 158. GigaGen
  • 159. Gilead
  • 160. GlaxoSmithKline
  • 161. GLyPharma
  • 162. Goodwin Biotechnology
  • 163. GP Pharm
  • 164. Grand River Aseptic Manufacturing
  • 165. Groninger
  • 166. GTCR
  • 167. Gulf Biotech
  • 168. HALIX
  • 169. Hameln Pharma
  • 170. Handl Therapeutics
  • 171. Hansa Biopharma
  • 172. Hapten Sciences
  • 173. Health Biotech
  • 174. Healthcare Pharmaceuticals
  • 175. Hepalink
  • 176. Hetero Drugs
  • 177. Hisun Pharmaceuticals USA
  • 178. Hookipa Pharma
  • 179. Hospira One 2 One
  • 180. Humanigen
  • 181. Hybio Pharmaceutical
  • 182. Hycult Biotech
  • 183. IDT Biologika
  • 184. IMA Group
  • 185. Immune Pharmaceuticals
  • 186. Immunex
  • 187. Infectious Disease Research Institute
  • 188. Injectalia
  • 189. Intas Pharmaceuticals
  • 190. Integrity Bio
  • 191. Irvine Pharmaceutical Services
  • 192. Istituto Biochimico Italiano Giovanni Lorenzini
  • 193. Janssen Pharmaceuticals
  • 194. JHL Biotech
  • 195. Johnson & Johnson
  • 196. JOINN Biologics
  • 197. Jubilant HollisterStier
  • 198. Kanda BioTech
  • 199. Kaneka Eurogentec
  • 200. Kawasaki Heavy Industries
  • 201. Kaysersberg Pharmaceuticals
  • 202. Kemwell Biopharma
  • 203. Klenzaids
  • 204. Kohlberg and Mubadala
  • 205. KUKA
  • 206. Laboratorios Farmaceuticos ROVI
  • 207. Laekna Therapeutics
  • 208. LamKap Bio
  • 209. Lava Therapeutics
  • 210. Liof Pharma
  • 211. Lonza
  • 212. LSNE Contract Manufacturing
  • 213. Lubrizol
  • 214. LuinaBio
  • 215. Lyophilization Technology
  • 216. M&O Perry Industries
  • 217. MabPlex
  • 218. Madison Dearborn Partners
  • 219. Marchesini Group
  • 220. MassBiologics
  • 221. Massman Automation Designs
  • 222. MaSTherCell
  • 223. MEDInstill
  • 224. Merck
  • 225. Microdermics
  • 226. Millmount Healthcare (acquired by PCI Pharma Services)
  • 227. Miltenyi Biotec
  • 228. Minaris Regenerative Medicine
  • 229. Mitsubishi Electric
  • 230. Moderna
  • 231. Mycenax Biotech
  • 232. Najít Technologies
  • 233. National Institutes of Health
  • 234. NBE-Therapeutics
  • 235. Nikon CeLL innovation
  • 236. Ningbo Zhengli Pharmaceutical Packing
  • 237. Nipro PharmaPackaging
  • 238. Nitto Avecia Pharma Services
  • 239. Nitto Denko Avecia
  • 240. Northway Biotechpharma
  • 241. Nova Laboratories
  • 242. Novartis
  • 243. Novasep
  • 244. Noveome Biotherapeutics
  • 245. Novex Innovations
  • 246. Novo Nordisk
  • 247. Ology Bioservices
  • 248. OmniChem
  • 249. Ompi
  • 250. OMRON Industrial Automation
  • 251. oncomed manufacturing
  • 252. Oncotec Pharma Produktion
  • 253. OPKO Health
  • 254. OPTIMA
  • 255. Oryn Therapeutics
  • 256. OSO Biopharmaceuticals Manufacturing (acquired by AMRI)
  • 257. Ottawa Hospital Research Institute
  • 258. Oxford BioMedica
  • 259. Pace Analytical
  • 260. PaizaBio
  • 261. Pall Life Sciences
  • 262. Panacea Pharmaceuticals
  • 263. Paragon Bioservices
  • 264. Particle Measuring Systems
  • 265. Partners Group
  • 266. Patheon
  • 267. PCI Pharma Services
  • 268. Penn Pharmaceutical Services
  • 269. Permira
  • 270. Pfizer
  • 271. Pfizer CentreOne
  • 272. Pharmaceutical Packaging Professionals
  • 273. Pierre Fabre
  • 274. Piramal Pharma Solutions
  • 275. Polpharma Biologics
  • 276. Polymun Scientific
  • 277. Praxis Pharmaceutical
  • 278. PrimaPharma
  • 279. Prince Sterilization Services
  • 280. PSC Biotech
  • 281. PYRAMID Laboratories
  • 282. Quality BioResources
  • 283. QureBio
  • 284. Recipharm
  • 285. Regeneron Pharmaceuticals
  • 286. Reliance Life Sciences
  • 287. Rentschler Biopharma
  • 288. Rentschler Fill Solutions
  • 289. Revance Therapeutics
  • 290. Roche
  • 291. Romaco
  • 292. Rommelag CMO
  • 293. RoslinCT
  • 294. ROTA
  • 295. Ruibo Bio-Technology
  • 296. Russian Direct Investment Fund (RDIF)
  • 297. Samsung Bioepis
  • 298. Samsung Biologics
  • 299. Sandoz
  • 300. Sanofi
  • 301. Saudi Biotechnology Manufacturing
  • 302. Schematic Engineering Industries
  • 303. SCHOTT
  • 304. ScinoPharm
  • 305. Seiko Epson
  • 306. Selecta Biosciences
  • 307. Sensorion
  • 308. Shengnuo Peptide
  • 309. Sherpa Clinical Packaging Packaging (acquired by PCI Pharma Services)
  • 310. Shibuya
  • 311. Shree Bhagwati Machtech (India)
  • 312. SialoCarb
  • 313. Siam Bioscience
  • 314. Siegfried Holding
  • 315. Singota Solutions
  • 316. Sio Gene Therapies
  • 317. SiO2 Medical Products
  • 318. SIRION Biotech
  • 319. Sirton Pharmaceuticals
  • 320. SKAN
  • 321. Snowbell Machines
  • 322. SP
  • 323. Square Pharmaceuticals
  • 324. Staubli
  • 325. Steriline
  • 326. Surrozen
  • 327. Swissfillon
  • 328. Symbiosis Pharmaceutical
  • 329. Symphogen
  • 330. SynCo Bio Partners
  • 331. Syngene
  • 332. Synklino
  • 333. Syntegon
  • 334. Sypharma
  • 335. National Health Research Institutes (NHRI)
  • 336. Takara Bio
  • 337. Tanvex BioPharma
  • 338. Taysha Gene Therapies
  • 339. Tekpak
  • 340. The Carlyle Group
  • 341. Therapure Biomanufacturing
  • 342. Thermo Fisher Scientific
  • 343. Tofflon
  • 344. Transcoject
  • 345. TriPharm Services (acquired by Alcami)
  • 346. TRUKING
  • 347. Tubulis
  • 348. U.S. Army Contracting Command
  • 349. UCB
  • 350. Ultragenyx Pharmaceutical
  • 351. Universal Robots
  • 352. University of Queensland
  • 353. USV
  • 354. Vanrx
  • 355. Vaxine
  • 356. VBI Vaccines
  • 357. Vetter Pharma
  • 358. VGXI
  • 359. Vibalogics
  • 360. Vaccine and Infectious Disease Organization (VIDO)
  • 361. Vigene Biosciences
  • 362. Viralgen
  • 363. VxP Biologics
  • 364. WACKER Biotech
  • 365. Waisman Biomanufacturing
  • 366. Watson-Marlow Fund
  • 367. West Pharmaceutical Services
  • 368. WuXi Biologics
  • 369. Wuxi Fortune Pharmaceutical
  • 370. Wuxi Griffin
  • 371. Yaskawa Electric
  • 372. Yposkesi
目次

Title:
Biologics Fill / Finish Services Market (2nd Edition)
by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins, Vaccines and Others), Scale of Operation (Preclinical / Clinical and Commercial), Key Therapeutic Areas, Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030.

Overview:

In order to meet the anticipated future demand for biologics fill / finish services in the American and European markets, contract service providers based in these regions have made significant investments in accruing additional capacity for drug product manufacturing and fill / finish. -- Chief Commercial Officer, large-sized company.

Over the last few decades, as a consequence of the therapeutic efficacy and favorable safety profiles of various marketed candidates and those under development, the biopharmaceutical industry has witnessed tremendous growth. The overwhelming success of this upcoming class of products has prompted both established and novice pharmaceutical innovators to develop assets in this arena. Currently, there are close to 400 approved products and more than 4,000 biologic candidates in clinical trials, being developed for the treatment of a wide variety of diseases. As the number of commercialized products and clinical stage therapy candidates increases, the demand for adequate manufacturing capacities and affiliated capabilities is also on the rise. In the production cycle, the (aseptic) fill / finish process is a crucial step. Biopharmaceutical fill / finish operations are relatively more complicated, involving sterilization of all affiliated components before use, filling in a sterile environment, and the use of appropriate post filling sterilization methods. Even minute errors during the aforementioned step can have catastrophic consequences, resulting in heavy losses for the innovator company. Therefore, it is important for companies to establish fill / finish related expertise and build / maintain the necessary infrastructure.

To meet some the abovementioned challenges, drug developers have not hesitated to outsource fill / finish operations to capable contract service providers. Currently, around 170 companies claim to be actively providing fill / finish services for biologics. As is generally the trend among service providers, stakeholders in this domain are making active attempts to adopt the latest technological innovations, in order to meet the growing demand for fill / finish services, reduce cost of operation / increase efficiency, and comply to evolving safety and regulatory requirements, and thereby, differentiate themselves amidst the competition. Over the last few years, the fill / finish services industry has witnessed more than 120 instances of expansion, most of which were intended to increase capacity. We believe that the companies involved this segment of the industry are likely to continue to undertake similar initiatives to cater to the growing needs of their clientele. In addition, significant partnership activity between sponsors and services providers has also been reported in the recent past; a substantial number of deals were observed to have been inked between vaccine developers and CMOs, focused on the fulfilment of fill / finish requirements for multiple vaccines against COVID-19. Considering the anticipated growth in the biologics market, the corresponding opportunity for fill / finish service providers is expected to grow at a steady pace over the coming years.

Scope of the Report:

The "Biologics Fill / Finish Services Market (2nd Edition) by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins, Vaccines and Others), Scale of Operation (Preclinical / Clinical and Commercial), Key Therapeutic Areas, Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030" report features an extensive study on the biologics fill / finish service providers. The study features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the companies offering fill / finish services for biopharmaceuticals / biologics, along with analyses based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill / finish facilities, types of packaging form (ampoules, cartridges, syringes and vials), type of biologic filled (ADC, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial), type of additional services offered (lyophilization, labelling, quality testing, storage and distribution services) and including details on fill / finish capacity and fill volume range.
  • A detailed competitiveness analysis of the fill / finish service providers based in different geographies offering services across various packaging types, based on supplier strength (in terms of experience and company size), service strength (in terms of number of fill / finish facilities, geographical reach and scale of operation) and types of biologics handled.
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific. Each profile provides an overview of the company, information on its service offerings, fill / finish facilities, financial information (if available), details on partnerships, expansions and recent awards and accolades, and an informed future outlook.
  • An analysis of the partnerships and collaborations focused on the fill / finish operations of biologic drug products, which were established since 2013, based on year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of biologics involved and location of fill / finish facilities involved.
  • A review of the recent expansions (since 2015) undertaken by biologics fill / finish service providers, including a detailed analysis based on various parameters, such as year of expansion, type of expansion (capacity expansion and new facility), type of packaging form, types of services offered, types of biologics involved, scale of operation (preclinical, clinical and commercial), the most active players and geographical location of the added facility.
  • An estimate of the global fill / finish capacity for filling of biologics, by taking into consideration the capacities of various fill / finish service providers. The fill / finish capacity has been analyzed in terms of number of units and volume of biologics filled, across various type of packaging containers (ampoules, cartridges, syringes, and vials), for the service providers distributed on the basis of company size (small, mid-sized and large) and geographical location (North America, Europe and Asia Pacific).
  • An informed estimate of the annual demand for fill / finish of the top 25 biologics, based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of these products.
  • A regional capability assessment framework, which compares the fill / finish capabiility across key geographies, based on a number of parameters, such as the number of biologic fill / finish service providers, number of biologic fill / finish facilities, number of biologic fill / finish partnerships inked in that particular geographical region, number of facility expansions and installed biologic fill / finish capacity in that particular geographical region.
  • An analysis to identify the key performance indicators for service providers engaged in this domain, based on information gathered via secondary research and primary research.
  • A case study to highlight the benefits of using robotic / automated equipment for aseptic fill / finish processes, providing a list of equipment manufacturers providing robots suitable for pharmaceutical operations.
  • A case study to highlight the role of ready-to-use packaging containers in aseptic fill / finish operations, providing a list of suppliers providing the ready-to-use components.
  • A discussion on the potential growth areas, such as growing biopharmaceutical pipeline, increasing outsourcing of fill / finish operations, rising focus on self-administration enabling drug delivery devices and growing opportunities in the Asia-Pacific region.

One of the key objectives of this report was to estimate the current market size and the future opportunity in the biologics fill / finish services market, over the coming decade. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, direct manufacturing costs, share of drug product manufacturing costs and outsourcing trends related to fill / finish operations, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and future opportunity have been further segmented on the basis of [A] types of packaging containers used for fill / finish (ampoules, cartridges, syringes and vials), [B] scale of operation (preclinical, clinical and commercial), [C] types of biologics (antibodies, cell therapy, gene therapy, oligonucleotides, recombinant proteins, vaccines and others), [D] key therapeutic areas (autoimmune disorders, cardiovascular disorders, infectious disorders, oncological disorders and other disorders), and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia-Pacific (Japan, China, South Korea, India and Australia), MENA, Latin America and Rest of the World). To account for the uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. The perceptions presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
  • Matt Delaney (Vice President Business Development & Marketing, Cytovance Biologics)
  • Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International)
  • Ales Sima (Business Development Manager, Oncomed Manufacturing)
  • Amit Chandra (Technology Watch Manager, Yposkesi)
  • Jos Vergeest (International Business Developer, HALIX)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading contract service providers with expertise in fill / finish services for biologics?
  • In which regions are majority of the biologic fill / finish facilities located?
  • What percentage of ampoules, cartridges, vials and syringes are filled annually with biologics?
  • Which partnership models are most commonly adopted by stakeholders in this industry?
  • What type of expansion initiatives are being carried out by players in this domain?
  • What is the current, global demand for biologic fill / finish services?
  • How is the current and future market opportunity likely to be distributed across key market segments

Chapter Outline:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the biologics fill / finish service providers market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to biopharmaceuticals and contract manufacturing. The chapter features a detailed discussion on the need for outsourcing within the biopharmaceutical industry and highlights the key operations outsourced by the biologic drug developers, including fill / finish. Additionally, the chapter highlights the key considerations for selecting a fill / finish service provider, along with the benefits and risks associated with outsourcing fill / finish operations.

Chapter 4 provides an overview of the overall biologics fill / finish contract services landscape. It includes information on close to 170 contract service providers currently engaged in this domain. Additionally, it features an in-depth analysis of service providers, based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill / finish facilities, types of packaging form (ampoules, cartridges, syringes and vials), type of biologic filled (ADC, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial), type of additional services offered (lyophilization, labelling, quality testing, storage and distribution services) and including details on fill / finish capacity and fill volume range.

Chapter 5 features a detailed competitiveness analysis of the service providers based in North America, Europe and Asia-Pacific. The companies within each geography have been compared on the basis of the type of packaging used for fill / finish services, supplier strength (considering experience and company size of service provider), service strength (considering number of fill / finish facilities, geographical reach, number of additional services offered and highest scale of operation) and type of biologics involved.

Chapter 6 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in North America. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook.

Chapter 7 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in Europe. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook.

Chapter 8 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in Asia-Pacific. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook.

Chapter 9 features a detailed analysis of the various collaborations and partnerships that have been inked amongst players since 2013. It includes a brief description of the partnership models (including acquisition, supply agreement, service alliance, merger and joint venture) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of agreement, the scale of operation of the project, focus area, types of services provided, types of biologics and location of the facilities where the project is to be executed.

Chapter 10 presents a detailed analysis of the expansions undertaken by various service providers to enhance fill / finish capabilities, based on various parameters, including year of expansion, type of expansion, geographical location of the facility, type of packaging container involved, scale of operation (as mentioned in the expansion terms), types of services offered, types of biologics filled, and expansion details (in terms of new area added to the existing facilities). It also highlights the most active players (in terms of number of instances) in the domain.

Chapter 11 features a comprehensive analysis of the global fill / finish capacity, by taking into consideration the container processing capacities of various fill / finish service providers (as available on respective company websites). The global biopharmaceutical fill / finish capacity has been distributed across number of packaging units, type of packaging container (ampoules, cartridges, syringes and vials), company size of the manufacturer (small, mid-sized and large) and geographical location (North America, Europe and Asia-Pacific).

Chapter 12 provides an estimate of the annual demand for fill / finish of top 25 biologics (in number of units of packaging containers), based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of the abovementioned products.

Chapter 13 features an analysis on the key performance indicators of service providers based on information available for top-ten biopharmaceutical players on various public platforms, as well as inputs obtained from primary research.

Chapter 14 presents a regional capability assessment framework, which compares the fill / finish capability across key geographies, based on a number of parameters, such as the number of biologics fill / finish service providers, number of biologics fill / finish facilities, number of biologics fill / finish partnerships inked in that particular geographical region, number of facility expansions and installed biologics fill / finish capacity in that particular geographical region.

Chapter 15 presents a comprehensive market forecast analysis, highlighting the likely growth of the biologics' fill / finish services market till the year 2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] types of primary packaging containers used for fill / finish (ampoules, cartridges, syringes and vials), [B] scale of operation (preclinical, clinical and commercial), [C] types of biologics filled (antibodies, cell therapy, gene therapy, oligonucleotides, recombinant proteins, vaccines and others), [D] key therapeutic areas (cancer, infectious diseases, autoimmune diseases, cardiovascular diseases and other indications, and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia (Japan, China, South Korea and India), MENA and Latin America and Rest of the World).

Chapter 16 includes a discussion on the various potential growth drivers for the biologics fill / finish services market, which takes into account the opportunities associated with the growing biopharmaceutical pipeline, increase in outsourcing of fill / finish operations, rising focus on self-administration of drugs / therapies and opportunities in the Asia-Pacific region.

Chapter 17 is a case study focused on use of robotic systems in fill / finish operations. It provides a list of equipment used by the service providers (wherever specified) for fill / finish operations, highlighting the purpose of robotics in various manufacturing operations. It also includes a list of companies providing robots for use in manufacturing processes carried in the pharmaceutical sector.

Chapter 18 is a case study on the use of ready-to-use packaging components in the aseptic fill / finish operations. It also provides a list of suppliers providing ready-to-use components.

Chapter 19 is a summary of the overall report wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the biologics fill / finish services market.

Chapter 20 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing and fill / finish domain. In this study, we spoke to Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Matt Delaney (Vice President Business Development & Marketing, Cytovance Biologics), Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International), Ales Sima (Business Development Manager, oncomed manufacturing), Amit Chandra (Technology Watch Manager, Yposkesi) and Jos Vergeest (International Business Developer, HALIX).

Chapter 21 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Biologics
  • 3.3. Need for Outsourcing Biologics-related Operations
  • 3.4. Introduction to Contract Manufacturing
  • 3.5. Commonly Outsourced Operations in the Biopharmaceutical Industry
    • 3.5.1. Biologics Fill / Finish Operations
  • 3.6. Basic Guidelines for Selecting a Fill / Finish Service Provider
  • 3.7. Advantages of Outsourcing Fill / Finish Operations
  • 3.8. Risks and Challenges of Outsourcing Fill / Finish Operations

4. BIOLOGICS FILL / FINISH SERVICE PROVIDERS: COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Biologics Fill / Finish Service Providers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Fill / Finish Facilities
    • 4.2.5. Analysis by Type of Packaging
    • 4.2.6. Analysis by Type of Biologics Filled
    • 4.2.7. Analysis by Scale of Operation
    • 4.2.8. Analysis by Additional Services Offered
    • 4.2.9. Information on Fill / Finish Capacity

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology and Key Parameters
  • 5.3. Biologics Fill / Finish Service Providers in North America
    • 5.4.1. Players Offering Services in Ampoules
    • 5.4.2. Players Offering Services in Cartridges
    • 5.4.3. Players Offering Services in Syringes
    • 5.4.4. Players Offering Services in Vials
  • 5.5. Biologics Fill / Finish Service Providers in Europe
    • 5.5.1. Players Offering Services in Ampoules
    • 5.5.2. Players Offering Services in Cartridges
    • 5.5.3. Players Offering Services in Syringes
    • 5.5.4. Players Offering Services in Vials
  • 5.6. Biologics Fill / Finish Service Providers in Asia-Pacific and RoW
    • 5.6.1. Players Offering Services in Ampoules
    • 5.6.2. Players Offering Services in Cartridges
    • 5.6.3. Players Offering Services in Syringes
    • 5.6.4. Players Offering Services in Vials

6. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA

  • 6.1. Chapter Overview
  • 6.2. AbbVie Contract Manufacturing
    • 6.2.1. Company Overview
    • 6.2.2. Service Portfolio
    • 6.2.3. Financial Information
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. BioPharma Solutions
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. BioReliance
    • 6.4.1. Company Overview
    • 6.4.2. Service Portfolio
    • 6.4.3. Financial Information
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. Catalent Biologics
    • 6.5.1. Company Overview
    • 6.5.2. Service Portfolio
    • 6.5.3. Financial Information
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. Patheon
    • 6.6.1. Company Overview
    • 6.6.2. Service Portfolio
    • 6.6.3. Financial Information
    • 6.6.4. Recent Developments and Future Outlook

7. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN EUROPE

  • 7.1. Chapter Overview
  • 7.2. Boehringer Ingelheim BioXcellence
    • 7.2.1. Company Overview
    • 7.2.2. Service Portfolio
    • 7.2.3. Financial Information
    • 7.2.4. Recent Developments and Future Outlook
  • 7.3. Lonza
    • 7.3.1. Company Overview
    • 7.3.2. Service Portfolio
    • 7.3.3. Financial Information
    • 7.3.4. Recent Developments and Future Outlook
  • 7.4. Pierre Fabre
    • 7.4.1. Company Overview
    • 7.4.2. Service Portfolio
    • 7.4.3. Financial Information
    • 7.4.4. Recent Developments and Future Outlook
  • 7.5. Recipharm
    • 7.5.1. Company Overview
    • 7.5.2. Service Portfolio
    • 7.5.3. Financial Information
    • 7.5.4. Recent Developments and Future Outlook
  • 7.6. Wacker Biotech
    • 7.6.1. Company Overview
    • 7.6.2. Service Portfolio
    • 7.6.3. Financial Information
    • 7.6.4. Recent Developments and Future Outlook

8. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC

  • 8.1. Chapter Overview
  • 8.2. Asymchem
    • 8.2.1. Company Overview
    • 8.2.2. Service Portfolio
    • 8.2.3. Financial Information
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Samsung Biologics
    • 8.3.1. Company Overview
    • 8.3.2. Service Portfolio
    • 8.3.3. Financial Information
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Syngene
    • 8.4.1. Company Overview
    • 8.4.2. Service Portfolio
    • 8.4.3. Financial Information
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. Takara Bio
    • 8.5.1. Company Overview
    • 8.5.2. Service Portfolio
    • 8.5.3. Financial Information
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. WuXi Biologics
    • 8.6.1. Company Overview
    • 8.6.2. Service Portfolio
    • 8.6.3. Financial Information
    • 8.6.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Biologics Fill / Finish Service Providers: List of Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Scale of Operation
    • 9.3.4. Analysis by Type of Service
    • 9.3.5. Analysis by Type of Process
    • 9.3.6. Analysis by Type of Biologic Involved
    • 9.3.7. Most Active Players: Analysis by Number of Partnerships
    • 9.3.8. Geographical Analysis
      • 9.3.8.1. Intercontinental and Intracontinental Agreements
      • 9.3.8.2. Analysis by Geographical Location of Facilities

10. RECENT EXPANSIONS

  • 10.1. Chapter Overview
  • 10.2. Biologics Fill / Finish Service Providers: Recent Expansions
    • 10.2.1. Analysis by Year of Expansion
    • 10.2.2. Analysis by Type of Expansion
    • 10.2.3. Analysis by Type of Packaging Form
    • 10.2.4. Analysis by Type of Service Offered
    • 10.2.5. Analysis by Type of Biologic Involved
    • 10.2.6. Analysis by Type of Biologic Involved and Scale of Operation
    • 10.2.7. Most Active Players: Analysis by Type of Service
    • 10.2.8. Geographical Analysis
    • 10.2.9. Expansions in North America: Analysis by Type of Service Offered and Type of
  • Biologic Involved
    • 10.2.10. Expansions in Europe: Analysis by Type of Service and Type of Biologic
    • 10.2.11. Expansions in Asia-Pacific: Analysis by Type of Service and Type of Biologic

11. CAPACITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
  • 11.3. Global Fill / Finish Capacity (by Number of Units Filled)
    • 11.3.1. Analysis by Type of Packaging
    • 11.3.2. Analysis by Company Size
    • 11.3.3. Analysis by Scale of Operation
    • 11.3.4. Analysis by Location of Headquarters
    • 11.3.5. Analysis by Location of Fill / Finish Facilities
  • 11.4. Global Fill / Finish Capacity (by Fill Volume)
    • 11.4.1. Analysis by Type of Packaging
    • 11.4.2. Analysis by Company Size
    • 11.4.3. Analysis by Scale of Operation
    • 11.4.4. Analysis by Location of Headquarters
    • 11.4.5. Analysis by Location of Fill / Finish Facilities
  • 11.5. Global Fill / Finish Capacity for Ampoules (by Number of Units Filled)
    • 11.5.1 Analysis by Company Size
    • 11.5.2 Analysis by Scale of Operation
    • 11.5.3. Analysis by Location of Headquarters
    • 11.5.4 Analysis by Location of Fill / Finish Facilities
  • 11.6. Global Fill / Finish Capacity for Ampoules (by Fill Volume)
    • 11.6.1. Analysis by Company Size
    • 11.6.2. Analysis by Scale of Operation
    • 11.6.3. Analysis by Location of Headquarters
    • 11.6.4. Analysis by Location of Fill / Finish Facilities
  • 11.7. Global Fill / Finish Capacity for Cartridges (by Number of Units Filled)
    • 11.7.1. Analysis by Company Size
    • 11.7.2. Analysis by Scale of Operation
    • 11.7.3. Analysis by Location of Headquarters
    • 11.7.4. Analysis by Location of Fill / Finish Facilities
  • 11.8. Global Fill / Finish Capacity for Cartridges (by Fill Volume)
    • 11.8.1. Analysis by Company Size
    • 11.8.2. Analysis by Scale of Operation
    • 11.8.3. Analysis by Location of Headquarters
    • 11.8.4. Analysis by Location of Fill / Finish Facilities
  • 11.9. Global Fill / Finish Capacity for Syringes (by Number of Units Filled)
    • 11.9.1 Analysis by Company Size
    • 11.9.2 Analysis by Scale of Operation
    • 11.9.3. Analysis by Location of Headquarters
    • 11.9.4 Analysis by Location of Fill / Finish Facilities
  • 11.10. Global Fill / Finish Capacity for Syringes (by Fill Volume)
    • 11.10.1. Analysis by Company Size
    • 11.10.2. Analysis by Scale of Operation
    • 11.10.3. Analysis by Location of Headquarters
    • 11.10.4. Analysis by Location of Fill / Finish Facilities
  • 11.11. Global Fill / Finish Capacity for Vials (by Number of Units Filled)
    • 11.11.1 Analysis by Company Size
    • 11.11.2 Analysis by Scale of Operation
    • 11.11.3. Analysis by Location of Headquarters
    • 11.11.4. Analysis by Location of Fill / Finish Facilities
  • 11.12. Global Fill / Finish Capacity for Vials (by Fill Volume)
    • 11.12.1. Analysis by Company Size
    • 11.12.2. Analysis by Scale of Operation
    • 11.12.3. Analysis by Location of Headquarters
    • 11.12.4. Analysis by Location of Fill / Finish Facilities
  • 11.13. Conclusion

12. DEMAND ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Assumptions and Methodology
  • 12.3. Global Demand for Biologics Fill / Finish Services
    • 12.3.1. Analysis by Type of Packaging
    • 12.3.2. Analysis by Type of Biologic
    • 12.3.3. Analysis by Therapeutic Area
    • 12.3.4. Analysis by Geographical Location
  • 12.4. Demand and Supply Analysis

13. KEY PERFORMANCE INDICATORS FOR BIOLOGIC MANUFACTURING AND FILL / FINISH

  • 13.1. Chapter Overview
  • 13.2. Biologics Manufacturing and Fill / Finish: Key Performance Indicators
    • 13.2.1. Financial Indicators
      • 13.2.1.1. Big Pharma Perspective
      • 13.2.1.2. Contract Manufacturers' Perspective
    • 13.2.2. Process and Capability-related Indicators
      • 13.2.2.1. Big Pharma Perspective
      • 13.2.2.2. Contract Manufacturers' Perspective
    • 13.2.3. Market Reputation-related Indicators
      • 13.2.3.1. Big Pharma Perspective
      • 13.2.3.2. Contract Manufacturers' Perspective
    • 13.2.4. Other Important Performance Indicators
    • 13.3.5. Conclusion

14. REGIONAL CAPABILITY ASSESSMENT

  • 14.1. Chapter Overview
  • 14.2. Assumptions and Key Parameters
  • 14.3. Biologics Fill / Finish Capabilities in North America
  • 14.4. Biologics Fill / Finish Capabilities in Europe
  • 14.5. Biologics Fill / Finish Capabilities in Asia-Pacific Region
  • 14.6. Concluding Remarks

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Forecast Methodology
  • 15.3. Overall Biologics Fill / Finish Services Market, 2021-2030
    • 15.3.1. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Packaging
    • 15.3.2. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Scale of Operation
    • 15.3.3. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Biologic
    • 15.3.4. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Therapeutic Area
    • 15.3.5. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Geographical Region
      • 15.3.5.1 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Countries
      • 15.3.5.2. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Packaging
      • 15.3.5.3. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Scale of Operation
      • 15.3.5.4. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Biologic
      • 15.3.5.5. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Therapeutic Area
      • 15.3.5.6. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Countries
      • 15.3.5.7. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Packaging
      • 15.3.5.8. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Scale of Operation
      • 15.3.5.9. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Biologic
      • 15.3.5.10. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Therapeutic Area
      • 15.3.5.11. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Countries
      • 15.3.5.12. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging
      • 15.3.5.13. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
      • 15.3.5.14. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
      • 15.3.5.15. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
  • 15.4. Biologics Fill / Finish Services Market for Ampoules, 2021-2030
    • 15.4.1. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Scale of Operation
    • 15.4.2. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Type of Biologic
    • 15.4.3. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Therapeutic Area
    • 15.4.4. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Geographical Region
      • 15.4.4.1. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Scale of Operation
      • 15.4.4.2. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Type of Biologic
      • 15.4.4.3. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Therapeutic Area
      • 15.4.4.4. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Scale of Operation
      • 15.4.4.5. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Type of Biologic
      • 15.4.4.6. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Therapeutic Area
      • 15.4.4.7. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
      • 15.4.4.8. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
      • 15.4.4.9. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
  • 15.5. Biologics Fill / Finish Services Market for Cartridges, 2021-2030
    • 15.5.1. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Scale of Operation
    • 15.5.2. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Type of Biologic
    • 15.5.3. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Therapeutic Area
    • 15.5.4. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Geographical Region
      • 15.5.4.1. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Scale of Operation
      • 15.5.4.2. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Type of Biologic
      • 15.5.4.3. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Therapeutic Area
      • 15.5.4.4. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Scale of Operation
      • 15.5.4.5. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Type of Biologic
      • 15.5.4.6. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Therapeutic Area
      • 15.5.4.7. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
      • 15.5.4.8. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
      • 15.5.4.9. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
  • 15.6. Biologics Fill / Finish Services Market for Syringes, 2021-2030
    • 15.6.1. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Scale of Operation
    • 15.6.2. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Type of Biologic
    • 15.6.3. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Therapeutic Area
    • 15.6.4. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Geographical Region
      • 15.6.4.1. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Scale of Operation
      • 15.6.4.2. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Type of Biologic
      • 15.6.4.3. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Therapeutic Area
      • 15.6.4.4. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Scale of Operation
      • 15.6.4.5. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Type of Biologic
      • 15.6.4.6. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Therapeutic Area
      • 15.6.4.7. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
      • 15.6.4.8. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
      • 15.6.4.9. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area
  • 15.7. Biologics Fill / Finish Services Market for Vials, 2021-2030
    • 15.7.1. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Scale of Operation
    • 15.7.2. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Type of Biologic
    • 15.7.3. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Therapeutic Area
    • 15.7.4. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Geographical Region
      • 15.7.4.1. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Scale of Operation
      • 15.7.4.2. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Type of Biologic
      • 15.7.4.3. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Therapeutic Area
      • 15.7.4.4. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Scale of Operation
      • 15.7.4.5. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Type of Biologic
      • 15.7.4.6. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Therapeutic Area
      • 15.7.4.7. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
      • 15.7.4.8. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
      • 15.7.4.9. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area

16. FUTURE GROWTH OPPORTUNITIES

  • 16.1. Chapter Overview
  • 16.2. Growing Biopharmaceutical Pipeline
  • 16.3. Increase in Outsourcing of Fill / Finish Activities
  • 16.4. Rising Focus on Self-Administration of Drugs
  • 16.5. Advances in Aseptic Fill / Finish Technologies
  • 16.6. Growing Opportunities in the Asia-Pacific Region

17. CASE STUDY: ROBOTIC SYSTEMS IN FILL / FINISH OPERATIONS

  • 17.1. Chapter Overview
  • 17.2. Contract Service Providers: List of Fill / Finish Equipment
  • 17.3. Role of Robotic Systems in Fill / Finish Operations
    • 17.3.1. Types of Robots Used in Pharmaceutical Operations
    • 17.3.2. Key Considerations for Selecting a Robotic System
    • 17.3.3. Advantages of Robotic Systems
    • 17.3.4. Disadvantages of Robotic Systems
  • 17.4. Companies Providing Robots for Use in the Pharmaceutical Industry
  • 17.5. Companies Providing Isolator based Aseptic Filling Systems
  • 17.6. Concluding Remarks

18. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH

  • 18.1. Chapter Overview
  • 18.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
    • 18.2.1. Advantages of Ready-to-Use Packaging Components
    • 18.2.2. Disadvantages of Ready-to-Use Packaging Components
  • 18.3. Companies Providing Ready-to-Use Packaging Components
  • 18.4. Concluding Remarks

19. CONCLUDING REMARKS

20. INTERVIEW TRANSCRIPTS

  • 20.1 Chapter Overview
  • 20.2 IDT Biologika
    • 20.2.1. Company Snapshot
    • 20.2.1. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer
  • 20.3 Cytovance Biologics
    • 20.3.1. Company Snapshot
    • 20.3.2. Interview Transcript: Matt Delaney, Vice President of Business Development and Marketing
  • 20.4. Syngene
    • 20.4.1. Company Snapshot
    • 20.4.2. Interview Transcript: Purushottam Singnurkar, Research Director and Head of Formulation Development
  • 20.5 oncomed manufacturing
    • 20.5.1. Company Snapshot
    • 20.5.2. Interview Transcript: Ales Sima, Business Development Manager
  • 20.6 Yposkesi
    • 20.6.1. Company Snapshot
    • 20.6.2. Interview Transcript: Amit, Technology Watch Manager
  • 20.7 HALIX
    • 20.7.1. Company Snapshot
    • 20.7.2. Interview Transcript: Jos Vergeest, International Business Developer

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Various Types of Biologics
  • Figure 3.2 Types of Third-Party Service Providers
  • Figure 3.3 Commonly Outsourced Operations
  • Figure 3.4 Steps Involved in Fill / Finish of Biologics
  • Figure 3.5 Key Considerations for Selecting a CMO Partner
  • Figure 3.6 Risks and Challenges of Outsourcing Biologics Fill / Finish Operations
  • Figure 4.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
  • Figure 4.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
  • Figure 4.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
  • Figure 4.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
  • Figure 4.5 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging
  • Figure 4.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Involved and Type of Packaging Form
  • Figure 4.7 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
  • Figure 4.8 Biologics Fill / Finish Service Providers: Distribution by Additional Services Offered
  • Figure 5.1 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in North America
  • Figure 5.2 Company Competitiveness Analysis: Players Offering Services in Ampoules (North America)
  • Figure 5.3 Company Competitiveness Analysis: Players Offering Services in Cartridges (North America)
  • Figure 5.4 Company Competitiveness Analysis: Players Offering Services in Syringes (North America)
  • Figure 5.5 Company Competitiveness Analysis: Players Offering Services in Vials (North America)
  • Figure 5.6 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in Europe
  • Figure 5.7 Company Competitiveness Analysis: Players Offering Services in Ampoules (Europe)
  • Figure 5.8 Company Competitiveness Analysis: Players Offering Services in Cartridges (Europe)
  • Figure 5.9 Company Competitiveness Analysis: Players Offering Services in Syringes (Europe)
  • Figure 5.10 Company Competitiveness Analysis: Players Offering Services in Vials (Europe)
  • Figure 5.11 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in (Asia-Pacific and Rest of the World)
  • Figure 5.12 Company Competitiveness Analysis: Players Offering Services in Ampoules (Asia-Pacific and Rest of the World)
  • Figure 5.13 Company Competitiveness Analysis: Players Offering Services in Cartridges (Asia-Pacific and Rest of World)
  • Figure 5.14 Company Competitiveness Analysis: Players Offering Services in Syringes (Asia-Pacific and Rest of the World)
  • Figure 5.15 Company Competitiveness Analysis: Players Offering Services in Vials (Asia-Pacific and Rest of the World)
  • Figure 6.1 AbbVie Contract Manufacturing: Overview of Service Portfolio
  • Figure 6.2 AbbVie: Annual Revenues, 2015-2020 (USD Billion)
  • Figure 6.3 BioPharma Solutions: Overview of Service Portfolio
  • Figure 6.4 BioReliance: Overview of Service Portfolio
  • Figure 6.5 Merck KGaA: Annual Revenues, 2014 - 9M 2020 (EUR Billion)
  • Figure 6.6 Merck KGaA: Annual Revenues by Business Segmnent, 9M 2020 (EUR Billion)
  • Figure 6.7 Catalent Biologics: Overview of Service Portfolio
  • Figure 6.8 Catalent Biologics: Annual Revenues, 2015-2020 (USD Billion)
  • Figure 6.9 Patheon: Overview of Service Portfolio
  • Figure 6.10 Thermo Fisher Scientific: Annual Revenues, 2014-9M 2020 (USD Billion)
  • Figure 7.1 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
  • Figure 7.2 Boehringer Ingelheim BioXcellence: Annual Revenues, 2014 - H1 2020 (EUR Billion)
  • Figure 7.3 Lonza: Overview of Service Portfolio
  • Figure 7.4 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Million)
  • Figure 7.5 Pierre Fabre: Overview of Service Portfolio
  • Figure 7.6 Pierre Fabre: Annual Revenues, 2015 - 2019 (EUR Billion)
  • Figure 7.7 Recipharm: Overview of Service Portfolio
  • Figure 7.8 Recipharm: Annual Revenues, 2012 - 9M 2020 (SEK Billion)
  • Figure 7.9 Recipharm: Revenues by Business Divisions, 9M 2020 (SEK Billion)
  • Figure 7.10 Wacker Biotech: Overview of Service Portfolio
  • Figure 7.11 Wacker Chemie: Annual Revenues, 2015 - 2020 (EUR Billion)
  • Figure 8.1 Asymchem: Overview of Service Portfolio
  • Figure 8.2 Asymchem: Annual Revenues, 2015-2019 (USD Million)
  • Figure 8.3 ChemPartner: Overview of Service Portfolio
  • Figure 8.4 Samsung Biologics: Overview of Service Portfolio
  • Figure 8.5 Samsung Biologics: Annual Revenues, FY 2016 - FY 2020 (KRW Billion)
  • Figure 8.6 Syngene: Overview of Service Portfolio
  • Figure 8.7 Syngene: Annual Revenues, FY 2016 - Q3 FY 2021 (INR Million)
  • Figure 8.8 Takara Bio: Overview of Service Portfolio
  • Figure 8.9 Takara Bio: Annual Revenues, FY 2016 - H1 FY 2021 (JPY Billion)
  • Figure 8.10 WuXi Biologics: Overview of Service Portfolio
  • Figure 8.11 WuXi Biologics: Annual Revenues, 2014 - H1 2020 (RMB Million)
  • Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2020
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Scale of Operation
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type of Service
  • Figure 9.5 Partnerships and Collaborations: Distribution by Types of Process
  • Figure 9.6 Partnerships and Collaborations: Distribution by Type of Biologic Involved and Type of Service Offered
  • Figure 9.7 Partnerships and Collaborations: Most Active Players
  • Figure 9.8 Partnerships and Collaborations: Geographical Analysis
  • Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.10 Partnerships and Collaborations: Distribution by Geographical Location of Facilities
  • Figure 10.1 Recent Expansions: Distribution by Year of Expansion, 2013-2021 (till January)
  • Figure 10.2 Recent Expansions: Distribution by Type of Expansion
  • Figure 10.3 Recent Expansions: Distribution by Type of Packaging Form
  • Figure 10.4 Recent Expansions: Distribution by Type of Expansion and Type of Service
  • Figure 10.5 Recent Expansions: Distribution by Type of Biologic Involved
  • Figure 10.6 Recent Expansions: Distribution by Type of Biologic Involved and Scale of Operation
  • Figure 10.7 Recent Expansions: Distribution by Geographical Location
  • Figure 10.8 Recent Expansions: Most Active Players
  • Figure 10.9 Recent Expansions: Distribution by Location of Expansion Project
  • Figure 10.10 Recent Expansions in North America: Distribution by Type of Service Offered and Type of Biologic Involved
  • Figure 10.11 Recent Expansions in Europe: Distribution by Type of Service and Type of Biologic
  • Figure 10.12 Recent Expansions in Asia-Pacific: Distribution by Type of Service and Type of Biologic
  • Figure 11.1 Capacity for Filling Ampoules: Distribution by Company Size (Sample Data Set)
  • Figure 11.2 Capacity for Filling Cartridges: Distribution by Company Size (Sample Data Set)
  • Figure 11.3 Capacity for Filling Syringes: Distribution by Company Size (Sample Data Set)
  • Figure 11.4 Capacity for Filling Vials: Distribution by Company Size (Sample Data Set)
  • Figure 11.5 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Type of Packaging (Million Units)
  • Figure 11.6 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Company Size (Million Units)
  • Figure 11.7 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Scale of Operation (Million Units)
  • Figure 11.8 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Headquarters (Million Units)
  • Figure 11.9 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Figure 11.10 Global Fill / Finish Capacity (by Fill Volume): Distribution by Type of Packaging (Kilo Liters)
  • Figure 11.11 Global Fill / Finish Capacity (by Fill Volume): Distribution by Company Size (Kilo Liters)
  • Figure 11.12 Global Fill / Finish Capacity (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
  • Figure 11.13 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
  • Figure 11.14 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Kilo Liters)
  • Figure 11.15 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size (Thousand Units)
  • Figure 11.16 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Range of Capacity by Company Size
  • Figure 11.17 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
  • Figure 11.18 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
  • Figure 11.19 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Figure 11.20 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size (Liters)
  • Figure 11.21 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Range of Capacity by Company Size (Liters)
  • Figure 11.22 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Scale of Operation (Liters)
  • Figure 11.23 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Headquarters (Liters)
  • Figure 11.24 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
  • Figure 11.25 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size (Thousand Units)
  • Figure 11.26 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Range of Capacity by Company Size
  • Figure 11.27 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
  • Figure 11.28 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
  • Figure 11.29 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Figure 11.30 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size (Liters)
  • Figure 11.31 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Range of Capacity by Company Size (Liters)
  • Figure 11.32 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Scale of Operation (Liters)
  • Figure 11.33 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Headquarters (Liters)
  • Figure 11.34 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
  • Figure 11.35 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Range of Capacity by Company Size (Thousand Units)
  • Figure 11.36 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Range of Capacity by Company Size (Thousand Units)
  • Figure 11.37 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
  • Figure 11.38 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
  • Figure 11.39 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Figure 11.40 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size (Liters)
  • Figure 11.41 Global Fill / Finish Capacity for Syringes (by Fill Volume): Range of Capacity by Company Size (Liters)
  • Figure 11.42 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Scale of Operation (Liters)
  • Figure 11.43 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Headquarters (Liters)
  • Figure 11.44 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
  • Figure 11.45 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size (Thousand Units)
  • Figure 11.46 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Range of Capacity by Company Size
  • Figure 11.47 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
  • Figure 11.48 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
  • Figure 11.49 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
  • Figure 11.50 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size (Kilo Liters)
  • Figure 11.51 Global Fill / Finish Capacity for Vials (by Fill Volume): Range of Capacity by Company Size (Kilo Liters)
  • Figure 11.52 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
  • Figure 11.53 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
  • Figure 11.54 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
  • Figure 12.1 Global Demand for Biologics Fill / Finish Services (Million Liters)
  • Figure 12.2 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Packaging (Kilo Liters)
  • Figure 12.3 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Biologic Involved (Kilo Liters)
  • Figure 12.4 Global Demand for Biologics Fill / Finish Services: Distribution by Therapeutic Area (Kilo Liters)
  • Figure 12.5 Global Demand for Biologics Fill / Finish Services: Distribution by Geographical Location (Kilo Liters)
  • Figure 12.6 Global Biologics Fill / Finish Services: Demand and Supply, 2021-2030
  • Figure 13.1 Biologics Manufacturing and Fill / Finish: Key Performance Indicators (KPIs)
  • Figure 13.2 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
  • Figure 13.3 Financial Indicators: Big Pharma Perspective
  • Figure 13.4 Financial Indicators: Contract Manufacturers' Perspective
  • Figure 13.5 Process / Capability-related Indicators: Comparative Analysis of KPIs of Big Pharma Companies
  • Figure 13.6 Process / Capability-related Indicators: Big Pharma Perspective
  • Figure 13.7 Process / Capability-related Indicators: Contract Manufacturers' Perspective
  • Figure 13.8 Market Reputation-related Indicators: Comparative Analysis of KPIs of Big Pharma Companies
  • Figure 13.9 Market Reputation-related Indicators: Big Pharma Perspective
  • Figure 13.10 Market Reputation-related Indicators: Contract Manufacturers' Perspective
  • Figure 13.11 Other Performance Indicators: Contract Manufacturers' Perspective
  • Figure 14.1 Regional Capability Assessment: Biologic Fill / Finish Capabilities in North America
  • Figure 14.2 Regional Capability Assessment: Biologic Fill / Finish Capabilities in Europe
  • Figure 14.3 Regional Capability Assessment: Biologic Fill / Finish Capabilities in Asia-Pacific and Rest of the World
  • Figure 14.4 Regional Capability Assessment: Comparison of Capabilities across Different Regions
  • Figure 15.1 Overall Biologics Fill / Finish Services Market, 2021-2030 (USD Billion)
  • Figure 15.2 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Packaging (USD Million)
  • Figure 15.3 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.4 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.5 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.6 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Geographical Region (USD Million)
  • Figure 15.7 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Countries (USD Million)
  • Figure 15.8 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Packaging (USD Million)
  • Figure 15.9 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.10 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.11 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.12 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Countries (USD Million)
  • Figure 15.13 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Packaging (USD Million)
  • Figure 15.14 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.15 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.16 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.17 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Countries (USD Million)
  • Figure 15.18 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging (USD Million)
  • Figure 15.19 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.20 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.21 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.22 Biologics Fill / Finish Services Market for Ampoules, 2021-2030 (USD Million)
  • Figure 15.23 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.24 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.25 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.26 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Geographical Region (USD Million)
  • Figure 15.27 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.28 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.29 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.30 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.31 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.32 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.33 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.34 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.35 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.36 Biologics Fill / Finish Services Market for Cartridges, 2021-2030 (USD Million)
  • Figure 15.37 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.38 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.39 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.40 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Geographical Region (USD Million)
  • Figure 15.41 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.42 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.43 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.44 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.45 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.46 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.47 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.48 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.49 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.50 Biologics Fill / Finish Services Market for Syringes, 2021-2030 (USD Million)
  • Figure 15.51 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.52 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.53 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.54 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Geographical Region (USD Million)
  • Figure 15.55 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.56 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.57 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.58 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.59 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.60 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.61 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.62 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.63 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.64 Biologics Fill / Finish Services Market for Vials, 2021-2030 (USD Million)
  • Figure 15.65 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.66 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.67 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.68 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Geographical Region (USD Million)
  • Figure 15.69 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.70 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.71 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.72 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.73 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.74 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 15.75 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.76 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
  • Figure 15.77 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 16.1 Growth Opportunities for Biologics Fill / Finish Service Providers
  • Figure 16.2 New Molecular Entities Approved by the FDA, 2011-2020
  • Figure 17.1 Key Considerations for Selecting a Robotic System
  • Figure 17.2 Advantages of Robotic Systems in Pharmaceutical Operations
  • Figure 18.1 Key Drivers of Ready-to-Use Platform
  • Figure 19.1 Concluding Remarks: Current Biologic Fill / Finish Service Providers Market Landscape Summary
  • Figure 19.2 Concluding Remarks: Recent Partnerships
  • Figure 19.3 Concluding Remarks: Recent Expansions
  • Figure 19.4 Concluding Remarks: Capacity Analysis
  • Figure 19.5 Concluding Remarks: Demand Analysis
  • Figure 19.6 Concluding Remarks: Market Sizing and Opportunity Analysis for Biologic Fill / Finish Services Market